Targeting

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

44 citing papers in PubMed, 78 citations in OpenAlex.

1. Acoziborole resistance associated mutations in Trypanosoma brucei CPSF3.PLoS pathogens · 2026
   Article
2. Recent Advancements in the Diversification and Applications of Boron-Containing Compounds in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
3. Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
4. FLL2 modulatesiScience · 2025
   Article
5. Transforming the chemotherapy of human African trypanosomiasis.Clinical microbiology reviews · 2025
   Review
6. Applications of CRISPR in Parasitology.Current pharmaceutical biotechnology · 2025
   Review
7. In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells.Scientific reports · 2024
   Article
8. Anticancer benzoxaboroles block pre-mRNA processing by directly inhibiting CPSF3.Cell chemical biology · 2024
   Article
9. Frontiers in immunology · 2024
   Article
10. The anticancer compound JTE-607 reveals hidden sequence specificity of the mRNA 3' processing machinery.Nature structural & molecular biology · 2023
    Article
11. Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer.Science advances · 2023
    Article
12. Elevated pre-mRNA 3' end processing activity in cancer cells renders vulnerability to inhibition of cleavage and polyadenylation.Nature communications · 2023
    Article
13. 3'-End Processing of Eukaryotic mRNA: Machinery, Regulation, and Impact on Gene Expression.Annual review of biochemistry · 2023
    Review
14. iScience · 2023
    Article
15. Comparative genomics and interactomics of polyadenylation factors for the prediction of new parasite targets: Entamoeba histolytica as a working model.Bioscience reports · 2023
    Article
16. Transcriptome profile of halofuginone resistant and sensitive strains ofFrontiers in microbiology · 2023
    Article
17. Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates.Nature microbiology · 2022
    Article
18. Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum.International journal for parasitology. Drugs and drug resistance · 2022
    Article
19. RBBP6 activates the pre-mRNA 3' end processing machinery in humans.Genes & development · 2022
    Article
20. A real-time fluorescence assay for CPSF73, the nuclease for pre-mRNA 3'-end processing.RNA (New York, N.Y.) · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

15 authors at 4 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as